Cryolife Inc (CRY) was Initiated by Canaccord Genuity to “Buy” and the brokerage firm has set the Price Target at $14. Canaccord Genuity advised their investors in a research report released on Apr 13, 2016.
Many Wall Street Analysts have commented on Cryolife Inc. Canaccord Genuity Initiated Cryolife Inc on Apr 13, 2016 to “Buy”, Price Target of the shares are set at $14.
On the company’s financial health, Cryolife Inc reported $0.13 EPS for the quarter, beating the analyst consensus estimate by $ 0.08 according to the earnings call on Feb 16, 2016. Analyst had a consensus of $0.05. The company had revenue of $39.80 million for the quarter, compared to analysts expectations of $39.38 million. The company’s revenue was up 7.0% compared to the same quarter last year. During the same quarter in the previous year, the company posted $0.04 EPS.
Cryolife Inc closed down -0.13 points or -1.18% at $10.88 with 62,423 shares getting traded on Monday. Post opening the session at $11, the shares hit an intraday low of $10.83 and an intraday high of $11.11 and the price fluctuated in this range throughout the day.Shares ended Monday session in Red.
In a different news, on Mar 9, 2016, C Elkins Ronald (director) sold 2,000 shares at $11.18 per share price. According to the SEC, on Mar 4, 2016, James P Mackin (CEO) purchased 10,000 shares at $10.91 per share price. On Mar 1, 2016, David C Gale (VP, Research & Development) sold 150 shares at $9.97 per share price, according to the Form-4 filing with the securities and exchange commission.
CryoLife Inc. (CryoLife) is a medical device company. The Company is engaged in medical device manufacturing and distribution and in the processing and distribution of implantable human tissues for cardiac and vascular surgeries. The Company operates in two segments: Medical Devices and Preservation Services. The Medical Devices segment includes external revenues from product sales of BioGlue BioFoam PerClot CardioGenesis cardiac laser therapy HeRO Graft and ProCol. The Preservation Services segment includes external services revenues from the preservation of cardiac and vascular tissues. The Company’s product BioGlue is a polymer consisting of bovine blood protein and an agent for cross-linking proteins which was developed for use in cardiac vascular pulmonary and surgical applications. The Company developed BioFoam to seal organs such as the liver and for use in cardiovascular surgeries and provide hemostasis in penetrating wounds and trauma.